drugset / Trial / NCT06466382
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Timeline
- Start
- 2025-03-31
- Primary completion
- 2027-03
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 2 unknown | — |
| Comparator | Carboplatin | Small molecule | 5 unknown | — |
| Comparator | Paclitaxel | Small molecule | 60 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | — |